Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Trial Summary
What is the purpose of this trial?
Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection timepoint. Ultimately, the integration of ctDNA into the clinical workflow has the potential to enhance cancer diagnosis, treatment, surveillance, and prognosis, and guide clinical decision-making in this era of personalized precision medicine.
Research Team
Melissa Reimers, M.D.
Principal Investigator
Washington University School of Medicine
Eligibility Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are monitored for early treatment response using circulating tumor DNA (ctDNA) for solid tumors
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Circulating Tumor DNA (ctDNA)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Washington University School of Medicine
Lead Sponsor
National Center for Advancing Translational Science (NCATS)
Collaborator
Roche Sequencing Solutions
Industry Sponsor
The V Foundation for Cancer Research
Collaborator
National Institute of General Medical Sciences (NIGMS)
Collaborator
Radiological Society of North America
Collaborator
National Center for Advancing Translational Sciences (NCATS)
Collaborator
The Foundation for Barnes-Jewish Hospital
Collaborator
Skandalaris
Collaborator